PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: Hôpital Saint-Louis, Azienda Ospedaliero-Universitaria Careggi, University of Florence, University Hospital Leipzig, Leipzig University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Boston Foundation, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417014657
Cites:
Cited by:
Related to: